A multiplex platform for the identification of ovarian cancer biomarkers

BACKGROUND: Currently, there are no FDA approved screening tools for detecting early stage ovarian cancer in the general population. Development of a biomarker-based assay for early detection would significantly improve the survival of ovarian cancer patients. METHODS: We used a multiplex approach t...

Descripción completa

Detalles Bibliográficos
Autores principales: Boylan, Kristin L. M., Geschwind, Kate, Koopmeiners, Joseph S., Geller, Melissa A., Starr, Timothy K., Skubitz, Amy P. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634875/
https://www.ncbi.nlm.nih.gov/pubmed/29051715
http://dx.doi.org/10.1186/s12014-017-9169-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634875/
https://www.ncbi.nlm.nih.gov/pubmed/29051715
http://dx.doi.org/10.1186/s12014-017-9169-6

Ejemplares similares